WCLC 2019 – A non-invasive complementary biomarker improves the efficacy of lung cancer screening


  • Elena Riboldi - Agenzia Zoe
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The combination of blood microRNA (miRNA) assay and low-dose computed tomography (LDCT) allows optimal screening intensity and reduces unnecessary LDCT repeats in lung cancer (LC) screening.

 

Why this matters

  • Screening by LDCT can reduce LC-specific mortality.
  • Adequate risk stratification is needed to choose the optimal screening interval.

 

Study design

  • The bioMILD trial prospectively enrolled 4119 volunteers; inclusion criteria were: aged 50-75, ≥30 pack-years, smoking stop ≤10 years.
  • At baseline, participants received LDCT and miRNA profiling.
  • LDCT threshold cut-off was set at 113 mm3.
  • The 24-miRNA signature classifier predicts 3 risk levels; subjects were defined miRNA-negative if classified at low risk or miRNA-positive if classified at intermediate/high risk.
  • LDCT and miRNA were tested independently with blind evaluation.
  • Participants were grouped into 3 categories: double positive (2-pos: LDCT-positive and miRNA-positive), single positive (1pos: LDCT-positive or miRNA-positive), double negative (2neg: LDCT-negative and miRNA-negative).
  • LDCT screening intervals were: 3-6 months (2pos), 1 year (1pos), 3 years (2neg).
  • Median observation period was 4.5 years.

 

Key results

  • Participants in the 2neg, 1pos, and 2pos groups were 2384 (58%), 1526 (37%), and 209 (5%), respectively.
  • After four screening runs, 115 LCs were diagnosed (2.8%).
  • Cumulative LC incidence was significantly different in the three groups: 0.6% for 2neg subjects, 3.8% for 1pos and 20.1% for 2pos (P
  • LC incidence within 3 years in the three groups was 0.1%, 2.5%, and 19.1%, respectively (P
  • LC risk was significantly higher in 1-pos and 2-pos subjects (HR 6.0 and 36.6, respectively).
  • LC mortality in the three groups was 0.1%, 0.6% and 3.8%, respectively (P
  • LC mortality was significantly higher in 1-pos and 2-pos subjects (HR 5.7 and 32.2, respectively).
  • Interval cancer incidence, proportion of stage I, and resected LC were not statistically different among groups.

 

Funding

  • Italian Association for Cancer Research (AIRC), Italian Ministry of Health, National Cancer Institute of Milan, US National Institutes of Health, Gensignia.

 

Expert commentary

“Reducing regular follow-up scans based on additional risk information is a way forward, but prospective large randomised clinical trials are needed to confirm safety of these approaches in nationwide programs.” Harry J. de Koning, MD, PhD, Erasmus MC (Rotterdam, Netherlands).

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit